PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

October 12, 2017: By Jon Swedien

PanOpticaPanOptica has secured $11 million in a Series B financing, the company announced Oct. 6.

The money will allow PanOptica to start a new Phase I/II study of a next-generation formulation of PAN-90806—a small molecule anti-vascular endothelial growth factor (anti-VEGF) eye drop—as monotherapy for up to three months of treatment in patients with neovascular age-related macular degeneration.

PanOptica said PAN-90806 has the potential to reduce injection burden and could lower treatment discontinuation rates and slow underlying disease progression through improved patient comfort, safety, acceptance, and adherence, especially in the chronic management phase of treatment.

In preclinical research using validated ocular angiogenesis models, topically administered PAN-90806 in the form of an eye drop suppressed the formation of new blood vessels, PanOptica said.

Financing was provided by Third Rock Ventures and SV Health Investors.

PanOptica is a private company based in Bernardsville, New Jersey.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility